Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00638690 · FLOW

Participant flow

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy · Source last updated 2014-04-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Abiraterone acetate plus prednisone/prednisolone administered as four 250 mg tablets of abiraterone acetate once daily plus 5 mg prednisone/5 mg prednisolone twice daily until disease progression.
    id
    FG000
    title
    Abiraterone Acetate
  2. description
    Placebo plus prednisone/prednisolone administered as four placebo tablets once daily plus 5 mg prednisone/5 mg prednisolone tablet twice daily until disease progression.
    id
    FG001
    title
    Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        655
      2. group Id
        FG001
        num Subjects
        335
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        22
      2. group Id
        FG001
        num Subjects
        5
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        2
      type
      Lost to Follow-up
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        797
      2. group Id
        FG001
        num Subjects
        398
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        116
      2. group Id
        FG001
        num Subjects
        56
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        681
      2. group Id
        FG001
        num Subjects
        342
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Abiraterone acetate plus prednisone/prednisolone administered as four 250 mg tablets of abiraterone acetate once daily plus 5 mg prednisone/5 mg prednisolone twice daily until disease progression.
    id
    FG000
    title
    Abiraterone Acetate
  2. description
    Placebo plus prednisone/prednisolone administered as four placebo tablets once daily plus 5 mg prednisone/5 mg prednisolone tablet twice daily until disease progression.
    id
    FG001
    title
    Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        655
      2. group Id
        FG001
        num Subjects
        335
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        22
      2. group Id
        FG001
        num Subjects
        5
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        2
      type
      Lost to Follow-up
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        797
      2. group Id
        FG001
        num Subjects
        398
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        116
      2. group Id
        FG001
        num Subjects
        56
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        681
      2. group Id
        FG001
        num Subjects
        342
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice